<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881386</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/0536 CCR3939</org_study_id>
    <nct_id>NCT01881386</nct_id>
  </id_info>
  <brief_title>Lactate Imaging as a Tumour Biomarker</brief_title>
  <official_title>Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to investigate whether measurements of lactate in tumours, made
      using a magnetic resonance technique similar to MRI, is an effective non-invasive method to
      detect whether some new targeted drugs are having their desired effect.

      The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be
      able to observe changes in tumour lactate levels in vivo, in response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response</measure>
    <time_frame>7 and 21 days post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of MRS lactate measurement</measure>
    <time_frame>Two baseline measurements taken at day -7 to 0 pre-treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between changes in post treatment MRS lactate measurements and serum lactate dehydrogenase</measure>
    <time_frame>Baseline and 7 and 21 days post treatment</time_frame>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphoma</arm_group_label>
    <description>Lymphoma patients before and after receiving standard CHOP therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Colorectal</arm_group_label>
    <description>Patients with metastatic colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <description>Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain</arm_group_label>
    <description>Patients with primary brain tumours and patients with cerebral lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Magnetic Resonance Spectroscopy</description>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Metastatic Colorectal</arm_group_label>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:lymphoma patients

          -  minimum lesion size of 2cm

          -  not pretreated but scheduled to be treated with CHOP (Cyclophosphamide,
             Hydroxydaunomycin,Oncovin and Prednisolone)

        Cohort 2:Colorectal patients

          -  metastatic disease of at least 2cm

          -  not pretreated

        Cohort 3:Phase 1 Drug Development

          -  minimum lesion size at least 2cm

        Cohort 4: Brain

          -  primary brain tumours receiving radiotherapy and temozolomide

          -  cerebral lymphoma receiving standard chemotherapy

        Exclusion Criteria:

          -  MRI incompatible metal implants

          -  Claustrophobia

          -  Inability to tolerate a 40 minute MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nandita deSouza, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute of Cancer Research and Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Cancer Research, United Kingdom</investigator_affiliation>
    <investigator_full_name>NdeSouza</investigator_full_name>
    <investigator_title>Professor of Translational Imaging</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <keyword>Lactate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

